Vers une hausse du marché des traitements de Parkinson

Decision Resources,
Inc., one of the world’s leading research and advisory firms focusing on
pharmaceutical and health care issues, finds that the Parkinson’s disease
(PD) market will grow steadily in the next ten years as populations age
and polytherapy becomes the norm in both the early and more advanced
stages of the disease.

A new study entitled Parkinson’s Disease finds that the newer, more
expensive therapies such as dopamine agonists will boost the number of PD
patients taking polytherapy, thus increasing the overall drug market’s
value.

« Novel therapies designed to improve patients’ responses to levodopa
will greatly expand the PD market over the next decade, » said Tricia
Nagle, analyst at Decision Resources. « Also fueling this sector will be
continued growth by current market leaders, including Novartis/Orion’s
Comtan, GlaxoSmithKline’s Requip, and Pfizer/Boehringer Ingelheim’s
Mirapex/Sifrol. Overall drug sales for PD in the major markets in 2012
will more than double 2002 sales. »

About Parkinson’s Disease

The chronic, progressive nature of PD and the fact that no currently
available treatments slow or stop the disease’s progression make it an
attractive target for drug development. Moreover, an ever-growing elderly
population that will lead to a steadily increasing number of PD sufferers
over the next decade renders the PD market a highly lucrative area of
opportunity.